Drug intelligence / Profile preview

QLS1209

Development stage: Phase 1
Lead developer: Qilu Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

QLS1209 is an investigational small molecule drug developed by Qilu Pharmaceutical. It is currently in Phase 1 clinical trials for the treatment of advanced solid tumors (neoplasms). The mechanism of action is believed to be inhibition of PKMYT1, a kinase involved in cell cycle regulation. PKMYT1 inhibition represents a synthetic lethality approach, particularly relevant for tumors with CCNE1 amplification or FBXW7/PPP2R1A mutations[1][2][3][4][5].

Targets

PKMYT1 (Protein kinase membrane associated tyrosine/threonine 1)

Beyond the preview

Go deeper on QLS1209.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLS1209.

Explore the full profile